Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.78 |
| ▸ | HTT | P42858 | 3/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647377 | 0.92 | L3MBTL1 (0.68) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL3884235 | 0.90 | HTT (0.65) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1645429 | 0.89 | THRB (0.67) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1646215 | 0.88 | MAPT (0.66) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1645537 | 0.88 | MAPT (1.00) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1644187 | 0.86 | L3MBTL1 (1.00) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1645318 | 0.86 | THRB (1.00) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1645408 | 0.84 | L3MBTL1 (0.86) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL3950210 | 0.83 | THRB (0.76) | MAPTHTTL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL1646235 | 0.82 | L3MBTL1 (0.78) | MAPTHTTL3MBTL1THRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | claimed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | claimed |
| CN-102105170-A | Antifungal combination therapy | F2G LTD | 2011-06-22 | — | — | CN | claimed |
| EP-2303329-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G Limited (GB) | 2011-04-06 | — | — | EP | claimed |
| CN-101679410-A | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2010-03-24 | — | — | CN | claimed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | claimed |
| WO-2009144473-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LIMITED (GB) | 2009-12-03 | — | — | WO | claimed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | claimed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | claimed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | claimed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | claimed |
| US-8604029-B2 | 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD BRITISH BODY CORPORATE (GB) | 2013-12-10 | — | — | US | disclosed |
| CN-101679410-B | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2013-11-27 | — | — | CN | disclosed |
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
| WO-2008062182-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2008-05-29 | — | — | WO | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | MAPT 2792/4885HTT 3105/4885L3MBTL1 3386/4885 |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | MAPT 1771/4885HTT 1809/4885L3MBTL1 4094/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | MAPT 2950/4885HTT 3347/4885L3MBTL1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.